IMS 2022 | ICARIA-MM: final OS analysis
Paul Richardson
• 26 Aug 2022
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares the results of the final analysis of the ICARIA-MM study (NCT02990338) which compares isatuximab, pomalidomide, and dexamethasone to pomalidomide and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma. The study showed a sustained progression-free survival (PFS) benefit as well as a strong trend toward a survival benefit for patients treated with the triplet combination, thereby supporting the use of isatuximab, pomalidomide and dexamethasone in the R/R setting. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
